SCHEMBL24311101

SCHEMBL24311101

CC(C)CCCC(C)CCC(=O)CCC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 1/20 0.55
LMNA P02545 1/20 0.48
MAPT P10636 2/20 0.42
PTPN1 P18031 3/20 0.41
KDM4C Q9H3R0 2/20 0.41
PHF8 Q9UPP1 2/20 0.41
KDM2A Q9Y2K7 2/20 0.41
KDM4A O75164 1/20 0.41
ACE P12821 1/20 0.39
GSTO1 P78417 1/20 0.39
GABRP O00591 2/20 0.38
GABRD O14764 2/20 0.38
GABRA1 P14867 2/20 0.38
GABRB1 P18505 2/20 0.38
GABRG2 P18507 2/20 0.38
GABRB3 P28472 2/20 0.38
GABRA5 P31644 2/20 0.38
GABRA3 P34903 2/20 0.38
GABRA2 P47869 2/20 0.38
GABRB2 P47870 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28887307 0.90 BLM (0.59) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL11913784 0.90 BLM (0.59) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL10537164 0.88 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL5878892 0.88 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL277518 0.88 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL1116070 0.88 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL27601852 0.88 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL10599018 0.84 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL5879060 0.84 BLM (0.63) BLMLMNAMAPTPTPN1KDM4C
SCHEMBL7585177 0.84 BLM (0.57) BLMLMNAMAPTPTPN1KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074866-A1 MODIFIED AMINE LIPIDS INTELLIA THERAPEUTICS, INC. 2025-03-06 US disclosed
CN-119285480-A Modified amine lipids 英特利亚治疗股份有限公司 2025-01-10 CN disclosed
US-12077483-B2 Modified amine lipids INTELLIA THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-20220119341-A1 MODIFIED AMINE LIPIDS INTELLIA THERAPEUTICS, INC. 2022-04-21 US disclosed
US-20220119341-A1 MODIFIED AMINE LIPIDS INTELLIA THERAPEUTICS, INC. 2022-04-21 US disclosed
CN-113260607-A Modified amine lipids 英特利亚治疗股份有限公司 2021-08-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12077483-B2 Modified amine lipids PHOSPHO1, SGMS1, SGMS2 BLM 1522/4885LMNA 1381/4885MAPT 1537/4885
US-20220119341-A1 MODIFIED AMINE LIPIDS PHOSPHO1, SGMS1, SGMS2 BLM 1522/4885LMNA 1381/4885MAPT 1537/4885
US-20250074866-A1 MODIFIED AMINE LIPIDS PHOSPHO1, SGMS1, SGMS2 BLM 1522/4885LMNA 1381/4885MAPT 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.